ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Rating) was the target of a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 14,900 shares, a drop of 77.5% from the December 31st total of 66,300 shares. Based on an average daily trading volume, of 19,100 shares, the days-to-cover ratio is presently 0.8 days.
Institutional Investors Weigh In On ProShares UltraShort Nasdaq Biotechnology
Several institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC lifted its stake in ProShares UltraShort Nasdaq Biotechnology by 234.0% during the second quarter. Citadel Advisors LLC now owns 34,972 shares of the company's stock worth $943,000 after purchasing an additional 24,501 shares during the last quarter. IMC Chicago LLC lifted its stake in ProShares UltraShort Nasdaq Biotechnology by 11.1% during the third quarter. IMC Chicago LLC now owns 23,335 shares of the company's stock worth $590,000 after purchasing an additional 2,332 shares during the last quarter. Finally, UBS Group AG increased its position in ProShares UltraShort Nasdaq Biotechnology by 54.7% during the first quarter. UBS Group AG now owns 1,371 shares of the company's stock worth $33,000 after buying an additional 485 shares during the period.
Get
ProShares UltraShort Nasdaq Biotechnology alerts:
ProShares UltraShort Nasdaq Biotechnology Stock Performance
Shares of BIS traded up $0.20 during midday trading on Thursday, hitting $18.36. The company had a trading volume of 8,844 shares, compared to its average volume of 25,385. The company's 50-day simple moving average is $19.13 and its 200-day simple moving average is $21.74. ProShares UltraShort Nasdaq Biotechnology has a 1 year low of $17.88 and a 1 year high of $35.64.
ProShares UltraShort Nasdaq Biotechnology Company Profile
(Get Rating)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.
Read More
- Get a free copy of the StockNews.com research report on ProShares UltraShort Nasdaq Biotechnology (BIS)
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
Receive News & Ratings for ProShares UltraShort Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares UltraShort Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
ProShares UltraShort納斯達克生物科技(納斯達克:BIS-GET評級)是空頭股數1月份大幅下跌的目標。截至1月15日,空頭股數共有14,900股,較12月31日的66,300股減少了77.5%。以日均成交量19,100股計算,目前天數與回補比率為0.8天。
機構投資者買入ProShares UltraShort納斯達克生物技術股
幾家機構投資者最近增持或減持了該公司的股份。Citadel Advisors LLC在第二季度將其在ProShares UltraShort納斯達克生物技術公司的持股比例提高了234.0%。Citadel Advisors LLC現在擁有34,972股該公司股票,價值943,000美元,上個季度又購買了24,501股。IMC Chicago LLC在第三季度增持了ProShares UltraShort納斯達克生物科技公司的股份11.1%。IMC Chicago LLC現在持有23,335股該公司股票,價值590,000美元,上個季度又購買了2,332股。最後,瑞銀集團在第一季度將其在ProShares UltraShort納斯達克生物科技公司的持倉增加了54.7%。瑞銀集團(UBS Group AG)在此期間又購買了485股,目前持有1,371股該公司股票,價值33,000美元。
到達
ProShares超短波納斯達克生物技術警報:
ProShares超短納斯達克生物科技股表現
在週四午盤交易中,國際清算銀行的股價上漲了0.2美元,達到18.36美元。該公司的成交量為8844股,而其平均成交量為25385股。該公司的50日簡單移動均線切入位為19.13美元,200日簡單移動均線切入位為21.74美元。ProShares UltraShort納斯達克生物科技的一年低點為17.88美元,一年高位為35.64美元。
ProShares UltraShort納斯達克生物技術公司簡介
(獲取評級)
ProShares超納斯達克生物科技(基金)只尋求一天的投資結果,不尋求較長時期的投資結果。基金尋求扣除費用和費用前的每日投資結果,相當於該指數每日業績的兩倍(200%)。超過一個交易日的基金回報將是這段時間內每一天的回報的復合結果,這很可能與同期納斯達克生物技術指數(該指數)的回報兩倍(200%)不同。
閱讀更多內容
- 免費獲取StockNews.com關於ProShares UltraShort納斯達克生物技術的研究報告
- 雪佛龍以750億美元的股票回購取悅股東
- 電子商務的未來:分析和新數據
- 列維·施特勞斯非常適合收益型投資者
- 3只小盤股有很大的上漲空間
- 馬倫汽車:好消息、壞消息和醜陋的前景
獲得ProShares UltraShort納斯達克生物科技日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ProShares UltraShort納斯達克生物技術和相關公司的最新新聞和分析師評級的每日摘要。